The report will be delivered in 2-3 business days.

Monoclonal Antibodies (MAbS) Global Market Report 2021 - By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular), By End Users (Hospitals, Private Clinics, Research Institute), COVID-19 Impact And Recovery

Starting Price : $5000.00 | Pages : 175 | Published : January 2021 | SKU CODE : 7182 | Format :


The monoclonal antibodies (MAbs) market consists of sales of monoclonal antibodies and related services. Monoclonal antibodies are used to enhance and suppress the immune response in various medical conditions and to treat various diseases such as cancer, cardiovascular and cerebrovascular diseases. This industry includes establishments that produce anti-cancer monoclonal antibodies to prevent metastasis by reducing cell proliferation, immunological monoclonal anti-bodies, neuropharmacological monoclonal anti-bodies, anti-infective monoclonal antibodies (MAbs), and other MAbs for human beings and animals.

The global monoclonal antibodies (MAbs) market is expected to grow from $106.87 billion in 2020 to $114.43 billion in 2021 at a compound annual growth rate (CAGR) of 7.1%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $179.56 billion in 2025 at a CAGR of 11.9%.

The Increasing prevalence of cost-efficient biosimilar monoclonal antibodies are driving the monoclonal antibodies market growth. The biosimilar aim is to curb the increasing healthcare cost and handle economic pressure from the patient pod and governments to reduce the cost of medication and increase access to treatment. Biosimilar is the pharmaceuticals that are developed to have similar properties to a biologic drug that has already been approved. A biosimilar monoclonal antibody costs 20%-25% lesser than the originator biologic drug. The number of clinical trials for a biosimilar is comparatively lesser than that of the original biologic drug and this proves to be the reason for the low cost of a biosimilar drug. In India, a new biosimilar policy called the ‘Guidelines on Similar Biologics’ prepared by the Central Drugs Standard Control Organization (CSDCO) is expected to give a major boost to the Indian biosimilar drugs industry.

Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to have a negative impact on the revenues of the monoclonal antibody drugs market. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, the revenue of US retail sales of homeopathic and herbal remedies was around $7.5 billion. These less expensive alternatives increase competitiveness for the biologics market putting downward pressure and limiting the demand for monoclonal antibody drugs.

The monoclonal antibodies market has been witnessing multiple strategic initiatives in recent years. Top companies in the market are strategically acquiring start-ups and mid-sized companies to broaden products and services. Strategic collaborations or acquisitions and partnership agreements help vendors expand their existing product portfolio and geographical reach. For instance, In February 2019, AbCellera and Novartis enter into a multi-target partnership to create an antibody-drug discovery platform and technology for treating clinically-relevant and neurodegenerative diseases. Furthermore, AbCellera collaborated with GlaxoSmithKline (GSK), a pharmaceutical company, for the discovery of monoclonal antibodies against an undisclosed membrane protein target. Merck completed the acquisition of Sigma-Aldrich Corp., a leading life science company. Post this acquisition, Merck has more than 50,000 employees, 72 manufacturing sites, and a presence in 67 countries worldwide. Companies in the industry are increasingly realigning their portfolios and pursue profitable inorganic growth opportunities. Additionally, M&A interest is also being fueled by stronger corporate balance sheets, liquid debt markets, and continued favorable interest rates globally

The Food and Drug Administration (FDA) is a federal agency of the United States Department of Health and Human Services, in the USA regulating the monoclonal antibodies and pharmaceutical drugs market. Increasing product launches and regulatory support for the treatment of rare diseases by USFDA is expected to support the monoclonal antibody therapeutics market growth. For instance, the U.S. Food and Drug Administration (FDA) granted accelerated approval to avelumab (BAVENCIO, EMD Serono, Inc.), a human monoclonal antibody, for the treatment of a rare disease, metastatic Merkel cell carcinoma (MCC). Similarly, the U.S FDA granted accelerated approval to immunotherapy product- TECENTRIQ (atezolizumab), a humanized, engineered monoclonal antibody, for the treatment of people with locally-advanced or metastatic urothelial carcinoma (mUC).

Major players in the market are Johnson & Johnson, Merck, AbbVie, Amgen, GlaxoSmithKline plc.

The countries covered in the global monoclonal antibodies (MAbs) market are Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA, Australia.

The regions covered in the global monoclonal antibodies (MAbs) market are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The global monoclonal antibodies (MAbs) market is segmented -

1) By Source: Murine, Chimeric, Humanized, Human

2) By Application: Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular, Others

3) By End Users: Hospitals, Private Clinics, Research Institute

    Table Of Contents

    1. Executive Summary

    2. Monoclonal Antibodies (MAbS) Market Characteristics

    3. Monoclonal Antibodies (MAbS) Market Trends And Strategies

    4. Impact Of COVID-19 On Monoclonal Antibodies (MAbS)

    5. Monoclonal Antibodies (MAbS) Market Size And Growth

    5.1. Global Monoclonal Antibodies (MAbS) Historic Market, 2015-2020, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Monoclonal Antibodies (MAbS) Forecast Market, 2020-2025F, 2030F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Monoclonal Antibodies (MAbS) Market Segmentation

    6.1. Global Monoclonal Antibodies (MAbS) Market, Segmentation  By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Murine

    Chimeric

    Humanized

    Human

    6.2. Global Monoclonal Antibodies (MAbS) Market, Segmentation  By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

     Anti-Cancer

    Immunological

    Anti-Infective Monoclonal Antibodies (Mabs)

    Neuropharmacological

    Cardiovascular And Cerebrovascular

    Others

    6.3. Global Monoclonal Antibodies (MAbS) Market, Segmentation  By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    Hospitals

    Private Clinics

    Research Institute  

    7. Monoclonal Antibodies (MAbS) Market Regional And Country Analysis

    7.1. Global Monoclonal Antibodies (MAbS) Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    7.2. Global Monoclonal Antibodies (MAbS) Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    8. Asia-Pacific Monoclonal Antibodies (MAbS) Market  

    8.1. Asia-Pacific Monoclonal Antibodies (MAbS) Market Overview  

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    8.3. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    8.4. Asia-Pacific Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    9. China Monoclonal Antibodies (MAbS) Market  

    9.1. China Monoclonal Antibodies (MAbS) Market Overview  

    9.2. China Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

    9.3. China Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

    9.4. China Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F,$ Billion

    10. India Monoclonal Antibodies (MAbS) Market  

    10.1. India Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    10.2. India Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    10.3. India Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    11. Japan Monoclonal Antibodies (MAbS) Market  

    11.1. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    11.2. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    11.3. Japan Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    12. Australia Monoclonal Antibodies (MAbS) Market  

    12.1. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    12.2. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    12.3. Australia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    13. Indonesia Monoclonal Antibodies (MAbS) Market  

    13.1. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    13.2. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    13.3. Indonesia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    14. South Korea Monoclonal Antibodies (MAbS) Market  

    14.1. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    14.2. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    14.3. South Korea Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    15. Western Europe Monoclonal Antibodies (MAbS) Market  

    15.1. Western Europe Monoclonal Antibodies (MAbS) Market Overview

    15.2. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    15.3. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    15.4. Western Europe Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    16. UK Monoclonal Antibodies (MAbS) Market  

    16.1. UK Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    16.2. UK Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    16.3. UK Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    17. Germany Monoclonal Antibodies (MAbS) Market  

    17.1. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    17.2. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    17.3. Germany Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    18. France Monoclonal Antibodies (MAbS) Market  

    18.5. France Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    18.6. France Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    18.7. France Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    19. Eastern Europe Monoclonal Antibodies (MAbS) Market  

    19.1. Eastern Europe Monoclonal Antibodies (MAbS) Market Overview

    19.2. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    19.3. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    19.4. Eastern Europe Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    20. Russia Monoclonal Antibodies (MAbS) Market  

    20.1. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    20.2. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    20.3. Russia Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    21. North America Monoclonal Antibodies (MAbS) Market  

    21.1. North America Monoclonal Antibodies (MAbS) Market Overview

    21.2. North America Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    21.3. North America Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    21.4. North America Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    22. USA Monoclonal Antibodies (MAbS) Market  

    22.1. USA Monoclonal Antibodies (MAbS) Market Overview

    22.2. USA Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    22.3. USA Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    22.4. USA Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    23. South America Monoclonal Antibodies (MAbS) Market  

    23.1. South America Monoclonal Antibodies (MAbS) Market Overview

    23.2. South America Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    23.3. South America Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    23.4. South America Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    24. Brazil Monoclonal Antibodies (MAbS) Market  

    24.1. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    24.2. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    24.3. Brazil Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    25. Middle East Monoclonal Antibodies (MAbS) Market  

    25.1. Middle East Monoclonal Antibodies (MAbS) Market Overview

    25.2. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    25.3. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    25.4. Middle East Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    26. Africa Monoclonal Antibodies (MAbS) Market  

    26.1. Africa Monoclonal Antibodies (MAbS) Market Overview

    26.2. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    26.3. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    26.4. Africa Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion

    27. Monoclonal Antibodies (MAbS) Market Competitive Landscape And Company Profiles

    27.1. Monoclonal Antibodies (MAbS) Market Competitive Landscape

    27.2. Monoclonal Antibodies (MAbS) Market Company Profiles

    27.2.1. Johnson & Johnson

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Merck

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. AbbVie

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Amgen

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Glaxosmithkline plc

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Monoclonal Antibodies (MAbS) Pipeline Analysis

    29. Key Mergers And Acquisitions In The Monoclonal Antibodies (MAbS) Market

    30. Monoclonal Antibodies (MAbS) Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Research Inquiries

    31.4. The Business Research Company

    31.5. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Table 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Table 3: Global Monoclonal Antibodies (MAbS) Market, Segmentation  By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 4: Global Monoclonal Antibodies (MAbS) Market, Segmentation  By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 5: Global Monoclonal Antibodies (MAbS) Market, Segmentation  By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 6: Global Monoclonal Antibodies (MAbS) Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 7: Global Monoclonal Antibodies (MAbS) Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 8: Asia-Pacific, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 9: Asia-Pacific, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 10: Asia-Pacific, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 11: China, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 12: China, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 13: China, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 14: India, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 15: India, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 16: India, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 17: Japan, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 18: Japan, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 19: Japan, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 20: Australia, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 21: Australia, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 22: Australia, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 23: Indonesia, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 24: Indonesia, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 25: Indonesia, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 26: South Korea, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 27: South Korea, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 28: South Korea, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 29: Western Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 30: Western Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 31: Western Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 32: UK, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 33: UK, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 34: UK, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 35: Germany, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 36: Germany, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 37: Germany, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 38: France, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 39: France, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 40: France, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 41: Eastern Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 42: Eastern Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 43: Eastern Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 44: Russia, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 45: Russia, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 46: Russia, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 47: North America, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 48: North America, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 49: North America, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 50: USA, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 51: USA, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 52: USA, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 53: South America, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 54: South America, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 55: South America, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 56: Brazil, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 57: Brazil, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 58: Brazil, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 59: Middle East, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 60: Middle East, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 61: Middle East, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 62: Africa, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 63: Africa, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 64: Africa, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Table 65: Johnson & Johnson Financial Performance
  • Table 66: Merck Financial Performance
  • Table 67: AbbVie Financial Performance
  • Table 68: Amgen Financial Performance
  • Table 69: Glaxosmithkline plc Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2015-2020, $ Billion
  • Figure 2: Global Forecast Market Growth, 2020-2025F, 2030F, $ Billion
  • Figure 3: Global Monoclonal Antibodies (MAbS) Market, Segmentation  By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 4: Global Monoclonal Antibodies (MAbS) Market, Segmentation  By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 5: Global Monoclonal Antibodies (MAbS) Market, Segmentation  By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 6: Global Monoclonal Antibodies (MAbS) Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 7: Global Monoclonal Antibodies (MAbS) Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 8: Asia-Pacific, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 9: Asia-Pacific, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 10: Asia-Pacific, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 11: China, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 12: China, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 13: China, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 14: India, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 15: India, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 16: India, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 17: Japan, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 18: Japan, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 19: Japan, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 20: Australia, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 21: Australia, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 22: Australia, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 23: Indonesia, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 24: Indonesia, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 25: Indonesia, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 26: South Korea, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 27: South Korea, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 28: South Korea, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 29: Western Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 30: Western Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 31: Western Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 32: UK, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 33: UK, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 34: UK, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 35: Germany, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 36: Germany, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 37: Germany, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 38: France, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 39: France, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 40: France, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 41: Eastern Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 42: Eastern Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 43: Eastern Europe, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 44: Russia, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 45: Russia, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 46: Russia, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 47: North America, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 48: North America, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 49: North America, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 50: USA, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 51: USA, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 52: USA, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 53: South America, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 54: South America, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 55: South America, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 56: Brazil, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 57: Brazil, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 58: Brazil, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 59: Middle East, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 60: Middle East, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 61: Middle East, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 62: Africa, Monoclonal Antibodies (MAbS) Market, Segmentation By Source, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 63: Africa, Monoclonal Antibodies (MAbS) Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 64: Africa, Monoclonal Antibodies (MAbS) Market, Segmentation By End Users, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
  • Figure 65: Johnson & Johnson Financial Performance
  • Figure 66: Merck Financial Performance
  • Figure 67: AbbVie Financial Performance
  • Figure 68: Amgen Financial Performance
  • Figure 69: Glaxosmithkline plc Financial Performance
Global Psoriasis Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Psoriatic Arthritis Treatment Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Regenerative Medicine For Cartilage Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Radiopharmaceuticals Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Remdesivir Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Research Antibodies and Reagents Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Rituximab Biosimilars Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
Global Respiratory Diseases Drugs Market Report 2021 – Opportunities And Strategies, Market Forecast And Trends
CAR-T Therapy Market 2021 - By Target Antigen (CD19, CD22, BCMA), By Application (Acute Lymphoblastic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Central Nervous System Drugs Market 2021 - By Type (Multiple Sclerosis (MS), Anti-Psychotic, Analgesics, Anti-Parkinson Drugs, Anesthetics, Anti-Epileptics, Anti-Depressants, Other CNS Drugs), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies/ Drug Stores), By Route Of Administration (Oral, Intravenous, Intranasal/ Inhalation), By Drug Classification (Branded Drugs, Generic Drugs), By Mode Of Purchase (Over-The-Counter Drugs, Prescription-Based Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Dry Eye Medication Market - By Prescription Type (OTC Drugs, Prescription Drugs) By Drug Variation (Branded, Generic) By Type Of Product (Aqueous, Evaporative, Aqueous and Evaporative) By Distribution Channel (Hospital Pharmacies, Eye Health Clinics, Retail Pharmacies, Online Pharmacies) By Delivery System (Liquid, Gel, Ointment, Others) And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Ophthalmology Drugs Market - By Type (Antglaucoma Drugs, Dry Eye Medication And Other Ophthalmological Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies/ Drug Stores And Others), By Drug Classification (Branded Drugs And Generic Drugs), By Mode Of Purchase (Prescription-Based Drugs, Over-The-Counter Drugs) And, By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Pharmaceutical Drugs Market - By Segments (Musculoskeletal Disorders Drugs, Cardiovascular Drugs, Oncology Drugs, Anti-Infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-Urinary Drugs, Respiratory Diseases Drugs, Gastrointestinal Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report
Musculoskeletal Drugs Market Global Briefing 2018
View Report
Respiratory Drugs Market Global Briefing 2018
View Report
Antisense And RNAi Therapeutics Market- By Technology (RNA Interference, Antisense RNA), By Route Of Administration (Intravenous injections, Intra Dermal injunctions, Other delivery methods), By Indication (Oncology, Cardiovascular device, Respiratory disorders, Neurological disorders, Infectious disease, Other diseases), And By Region, Opportunities And Strategies – Global Forecast To 2030
View Report

Call Us

+1 3156230293

(Americas)

+44 2071930708

(Europe)

+91 8897263534

(Asia & Others)